PMC5505919_01
Clinical course during treatment with infliximab. PSL: prednisolone, MTX: methotrexate, IgE: immunoglobulin E
1349-7235-56-1585-g001.jpg
PMC5505919_01_1349-7235-56-1585-g001.jpg
g001
After the discontinuation of infliximab (last injection: May 2012, 52nd injection), her skin symptoms disappeared, and her eosinophil count returned to a normal value within approximately three months (Fig. 1).
Clinical course during treatment with adalimumab, tocilizumab, and golimumab. PSL: prednisolone, MTX: methotrexate, IgG: immunoglobulin G, IgE: immunoglobulin E
1349-7235-56-1585-g002.jpg
PMC5505919_01_1349-7235-56-1585-g002.jpg
g002
Increasing her oral PSL dose (10 mg/day) resolved the itching and eosinophilia (Fig. 2). Consequently, the skin symptoms disappeared, and the eosinophil count and total serum IgE levels returned to their normal ranges within a few months (Fig. 2). Her eosinophil count has remained at <=1,000 /muL or less (mostly around 500 /muL) while on golimumab (Fig. 2), and her RA disease activity is well-controlled (DAS28-CRP: <2.0).